- Cell-based therapeutics developer ReNeuron said it had received a notice of allowance for a patent application in the US.

A notice of allowance was issued by the United States Patent & Trademark Office to indicate that an invention qualified for a patent.

The patent application was entitled 'Phenotype profile of human retinal progenitor cells'.

The company said the allowed patent protected the composition of its hRPC cell-based therapeutic candidate for retinal diseases.

'This notification of allowance in the US adds further intellectual property protection to the hRPC technology, which already has patent protection in a number of other major territories including Europe, Japan and Australia,' it added.

Story provided by